In this final section, we examine the current preclinical literature, summarised in Table 3, where strategies to suppress MYC activity are combined with a range of DDR inhibitors, exploring therapeutic options that may be especially relevant in DDR-defective cancers or those with high replication stress. This evidence concerns the gene MYC and cancer.